Revenue edged down 3% to HUF 203.4 bln. Direct cost of sales dropped 26pc to HUF 61.2 bln, lifting gross profit 12% to HUF 142.2 bln.
Richter booked net financial income of HUF 15.6 bln for the quarter, after a HUF 17.1 bln financial loss in the base period.
Earnings per share came to HUF 373 for the period.
Richter affirmed guidance for full-year pharmaceutical revenue, at a constant exchange rate, at EUR 2.15 bln-2.25 bln, rising in the "low-to-mid-teens" in percent.
First-quarter pharmaceutical sales — calculated at a constant HUF/EUR exchange rate of 382 — climbed 16%, boosted by higher turnover of Richter's antipsychotic cariprazine and women's healthcare products, Richter said.
Royalty income from Vraylar, one of the brand names for cariprazine, climbed 22% to HUF 49.4 bln. Estimated sales of Vraylar for 2024 is expected to be around USD 3.4 bln, according to earlier guidance by Richter's U.S. peer AbbVie, Richter noted.
Revenue of the women's healthcare segment climbed 17% to HUF 74.2 bln.
Richter had retained earnings of HUF 1.134 tln at the end of March, its balance sheet shows.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
